S. Charleson

Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts

Stacia Kargman, S. Charleson, Mark E. Cartwright et al. · Gastroenterology · 1996 · 465 citations · Full text

Life Sciences, Biochemistry, Pharmacology +12

Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2

Denis Riendeau, M. David Percival, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 460 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

Petpiboon Prasit, Z Wang, Christine Brideau et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 429 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +9

Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles

Chi‐Chung Chan, S. Boyce, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 399 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes.

John Woods, Jilly F. Evans, Diane Ethier et al. · The Journal of Experimental Medicine · 1993 · 395 citations · Full text

Life Sciences, Biochemistry, Cell Biology +14